Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ExpreS2ion, Mucosis, and University of Copenhagen Receive Eurostars Grant

Published: Thursday, September 27, 2012
Last Updated: Thursday, September 27, 2012
Bookmark and Share
Eurostars™ grant for the pre-clinical development of an innovative placental malaria vaccine.

ExpreS2ion Biotechnologies and Mucosis, along with University of Copenhagen have announced that they have been awarded a Eurostars™ grant with a total budget of over €1 million for the pre-clinical development of an innovative placental malaria vaccine.

This collaboration will apply novel vaccine technologies developed at Mucosis and ExpreS2ion to a malaria antigen developed at University of Copenhagen in a project funded by The Danish National Advanced Technology Foundation.

This vaccine development program aims to provide women in high-risk areas lifelong protection against malaria infection.

Thomas Johnston, CEO of Mucosis, commented: "This Eurostars™ funded collaboration will leverage the strengths of our Mimopath mucosal vaccine platform in combination with the contributions of our two prestigious partners in a high-burden disease area. We see this opportunity as a further validation of our platform and its potential to combat the most difficult of infectious diseases."

Dr. Charlotte Dyring, CEO of ExpreS2ion, said: "We are excited that we have secured this grant and that we will be collaborating with Mucosis and their innovative vaccine delivery approaches, and with the team at UCPH that has discovered and progressed the new promising placental malaria vaccine antigen. This collaboration will allow us to apply glycosylation engineering to the ExpreS2 platform, thus widening the potential of this efficient platform for production of recombinant proteins. The consortium members have specific complementary know-how and expertise that ensure an efficient development path in addressing a substantial global health need."

Dr. Ali Salanti, Associate Professor University of Copenhagen, said: "Vaccines are one of the most efficient health interventions; however development of a malaria vaccine remains a substantial challenge. Furthermore, a malaria vaccine to protect pregnant women from malaria would ideally offer long lasting protection, and conventional vaccine methods so far do not deliver this. In this new collaboration we will have the opportunity to apply novel vaccine technologies developed at Mucosis and Expres2ion to our malaria vaccine antigen developed at University of Copenhagen, with the aim to develop such a vaccine that can offer women long term protection against malaria."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Mucosis Receives Financial Support from the Dutch Government
Company receives an innovation credit line of up to €5 million for its SynGEM® program.
Friday, May 23, 2014
Mucosis Announces a Strategic Partnership with Changchun BCHT Biotechnology
Company raises EUR 5 million in a new financing round.
Wednesday, April 16, 2014
Mucosis Appoints Thomas Johnston to CEO
Mr. Johnston joined Mucosis as Chief Business Officer in May 2011, and succeeds Govert Schouten who is leaving the Company to found an internet start-up.
Monday, September 17, 2012
Mucosis Announces Positive Proof-Of-Concept Data for Mimopath® Platform in Humans
Mimopath®-based vaccines are able to produce balanced immune responses in both circulating blood and the respiratory tract.
Monday, May 14, 2012
Mucosis Announces Publication of Preclinical Data of Novel Influenza Vaccines
Mucosally administered Mimopath-based influenza vaccine protects against both homologous and heterologous challenge.
Thursday, May 03, 2012
Mucosis Announces New Scientific Advisory Board
Professors Jiri Mestecky, Willem van Eden and Peter J. Openshaw appointed to Scientific Advisory Board.
Friday, November 18, 2011
Mucosis Appoints Thomas Johnston as Chief Business Officer
Thomas Johnston will have global responsibility for the licensing and marketing of Mucosis’s technologies, negotiating corporate partnerships and other strategic alliances.
Monday, June 06, 2011
Mucosis Appoints Thomas Johnston as Chief Business Officer
Thomas have global responsibility for the licensing and marketing of Mucosis’s technologies, negotiating corporate partnerships and other strategic alliances.
Wednesday, May 18, 2011
Scientific News
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
Ebola Vaccine Trial Begins in Senegal
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
Cancer Discovery Links Experimental Vaccine and Biological Treatment
A new study at the University of Wisconsin-Madison has linked two seemingly unrelated cancer treatments that are both now being tested in clinical trials.
Study Reveals New Method to Develop More Efficient Drugs
A new study suggests a new approach to develop highly-potent drugs which could overcome current shortcomings of low drug efficacy and multi-drug resistance in the treatment of cancer as well as viral and bacterial infections.
Creating More Potent Vaccines
Yale researchers uncovered a new role for a type of immune cell, known as regulatory T cells, in promoting long-term immunity.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!